13价肺炎球菌结合疫苗诱导的血清和黏膜抗体反应与实验性6B型肺炎链球菌定植之间关联较差
在马拉维健康成人中,PCV13对实验性6B型肺炎链球菌定植的保护效力为62%。接种PCV13后4-6周血清IgG和鼻黏膜IgG/IgA抗荚膜多糖抗体高于安慰剂组并持续至少一年。但攻击前抗体水平在发生定植与未定植者间无显著差异,提示疫苗诱导的抗体与保护不直接相关。
要点
- PCV13对实验性6B型肺炎链球菌定植的保护效力为62%。
- 接种后4-6周血清IgG和鼻黏膜IgG/IgA抗体高于安慰剂组,持续至少一年。
- 攻击前抗体水平在定植者与未定植者间无显著差异。
核心结论
- 尽管PCV13对健康马拉维成人实验性6B型肺炎链球菌定植有高保护效力,但疫苗诱导的强效全身和黏膜抗荚膜多糖结合抗体与保护不直接相关。
研究设计与样本
- 在马拉维健康年轻成人中开展的随机对照试验,204名受试者接种PCV13或安慰剂,至少4周后鼻内接种6B型肺炎链球菌以建立定植。
- 在基线、接种后4周(接种前7天)、接种后2、7、14天及超过1年时采集外周血和鼻黏膜衬液。
- 采用世界卫生组织标准化的酶联免疫吸附试验测定血清和鼻黏膜衬液中抗6B型荚膜多糖IgG和IgA抗体浓度。
主要发现
- PCV13接种组在接种后4至6周时血清IgG和鼻黏膜IgG/IgA抗6B型荚膜多糖结合抗体高于安慰剂组,且至少持续至接种后一年。
- 鼻内攻击6B型肺炎链球菌后,无论是否发生实验性定植,血清或鼻黏膜抗荚膜多糖IgG结合抗体滴度均无显著变化。
- 攻击前PCV13诱导的血清IgG和鼻黏膜IgG/IgA抗6B型荚膜多糖结合抗体滴度在发生实验性定植者与未定植者之间无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal carriage is the primary reservoir for transmissionand a prerequisite for invasive pneumococcal disease. Pneumococcal Conjugate Vaccine 13 (PCV13) showed a 62% efficacy in protection against experimental Streptococcus pneumoniae serotype 6B (Spn6B) carriage in a controlled human infection model (CHIM) of healthy Malawian adults. We, therefore, measured humoral responses to experimental challenge and PCV-13 vaccination and determined the association with protection against pneumococcal carriage. METHODS: We vaccinated 204 young, healthy Malawian adults with PCV13 or placebo and nasally inoculated them with Spn6B at least four weeks post-vaccination to establish carriage. We collected peripheral blood and nasal lining fluid at baseline, 4 weeks post-vaccination (7 days pre-inoculation), 2, 7, 14 and > 1 year post-inoculation. We measured the concentration of anti-serotype 6B Capsular Polysaccharide (CPS) Immunoglobulin G (IgG) and IgA antibodies in serum and nasal lining fluid using the World Health Organization (WHO) standardised enzyme-linked immunosorbent assay (ELISA). RESULTS: PCV13-vaccinated adults had higher serum IgG and nasal IgG/IgA anti-Spn6B CPS-specific binding antibodies than placebo recipients 4 to 6 weeks post-vaccination, which persisted for at least a year after vaccination. Nasal challenge with Spn6B did not significantly alter serum or nasal anti-CPS IgG binding antibody titers with or without experimental pneumococcal carriage. Pre-challenge titers of PCV13-induced serum IgG and nasal IgG/IgA anti-Spn6B CPS binding antibodies did not significantly differ between those that got experimentally colonised by Spn6B compared to those that did not. CONCLUSION: This study demonstrates that despite high PCV13 efficacy against experimental Spn6B carriage in young, healthy Malawian adults, robust vaccine-induced systemic and mucosal anti-Spn6B CPS binding antibodies did not directly relate to protection.
引用
- Tembo G, Mayuni M, Kamng'ona R, et al. Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation. Vaccine. 2024. PMID: 38570270. doi:10.1016/j.vaccine.2024.03.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。